Result of AGM

RNS Number : 0925W

Renalytix PLC

17 December 2021

 

Renalytix plc

("Renalytix" or the "Company")  

Result of AGM

LONDON and SALT LAKE, 17 December 2021   - Renalytix (NASDAQ: RNLX) (LSE: RENX) announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

The results of the AGM are detailed below:

Resolution	In Favour			Against			Withheld
	Votes	%		Votes	%		Votes
1	36,309,096	99.95%		16,442	0.05%		40,498
2	25,272,488	70.34%		10,658,539	29.66%		26,932
3	27,437,320	76.36%		8,493,707	23.64%		26,932
4	36,289,799	99.81%		67,343	0.19%		8,894
5	36,339,057	99.95%		18,085	0.05%		8,894
6	36,337,208	99.95%		16,694	0.05%		12,134
7	36,339,655	99.95%		17,268	0.05%		9,113
8	35,826,173	98.54%		529,873	1.46%		9,990
9	27,776,213	77.27%		8,170,453	22.73%		11,293
10	35,891,613	99.94%		21,157	0.06%		45,189

For further information, please contact:  

Renalytix plc		www.renalytix.com
James McCullough, CEO		Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker)		Tel: [phone]
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker)		Tel: [phone]
Gary Clarence / Daniel Adams
Walbrook PR Limited	Tel: [phone]  or  [e-mail]
Paul McManus / Lianne Applegarth		Mob: [phone]

About KidneyIntelX

KidneyIntelX is a first-of-kind solution that enables early-stage diabetic kidney disease (DKD) progression risk assessment by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems, and employs a proprietary algorithm to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.

About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit  www.kidneyintelx.com ). For more information, visit  www.renalytix.com .

 

END

 

 

RAGBUBDDSXBDGBR